Last reviewed · How we verify
SPD503-PM
SPD503-PM is a small molecule drug that targets the serotonin receptor.
SPD503-PM is a small molecule drug that targets the serotonin receptor. Used for Obsessive-compulsive disorder, Major depressive disorder.
At a glance
| Generic name | SPD503-PM |
|---|---|
| Also known as | Intuniv |
| Sponsor | Shire |
| Drug class | Serotonin receptor antagonist |
| Target | 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It works by selectively binding to the serotonin receptor, which helps to reduce symptoms of certain conditions. This mechanism of action is thought to be beneficial for treating conditions such as obsessive-compulsive disorder and major depressive disorder.
Approved indications
- Obsessive-compulsive disorder
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Efficacy and Safety of SPD503 in Combination With Psychostimulants (PHASE3)
- Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |